<DOC>
	<DOC>NCT00874497</DOC>
	<brief_summary>Phase 2a multicenter, randomized, double-blind, placebo-controlled study to assess the pharmacodynamics, efficacy, and safety of tetomilast in patients with emphysema.</brief_summary>
	<brief_title>Pilot Study of Tetomilast in Chronic Obstructive Pulmonary Disease (COPD) Associated With Emphysema</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Emphysema</mesh_term>
	<criteria>Male or female, 4075 yrs old,inclusive. Rating of greater than or equal to 1 on the Goddard scale in assessment of emphysema severity by HRCT. FEV1: FVC greater than 70% predicted. At least 1 documented COPD exacerbation within the past year but not within 8 weeks of randomization. Current or former smokers with a cigarette smoking history of at least 20 packyears (or equivalent) and whose smoking status has not changed 60 days prior to screening. Patients with asthma, active tuberculosis or bronchiectasis. A respiratory tract infection within 30 days prior to the screening visit. Any malignancy within the last 5 years with the exception of nonmelanomatous skin cancer. Uncontrolled cardiovascular, endocrine, blood, or nervous system disorders. Uncontrolled condition with COPD exacerbation of level 2 or 3 in the 8week period prior to randomization. Systemic use of corticosteroids or other immunosuppressive agents within 30 days of the screening visit. Subjects taking anticoagulants.</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>